OKYO Pharma grants CMO 20,000 common shares

Mantelli Flavio reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 07/22/2026 - 04:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Mantelli Flavio reported acquisition or exercise transactions in this Form 4 filing.

OKYO Pharma Ltd’s chief medical officer, Flavio Mantelli, received a grant of 20,000 shares of common stock on July 21, 2026. The award was recorded at $1.40 per share as direct ownership, and Mantelli now directly holds 20,000 shares of OKYO Pharma common stock.

Insider Trade Summary

Grant/Award: 20,000 shares

Grant/Award 1 txn

Insider Mantelli Flavio

Role CHIEF MEDICAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	COMMON STOCK	20,000	$1.40	$28K

Holdings After Transaction: COMMON STOCK — 20,000 shares (Direct)

Key Figures

Shares granted: 20,000 shares of common stock Grant price: $1.40 per share Post-transaction holdings: 20,000 shares

3 metrics

Shares granted 20,000 shares of common stock Grant, award, or other acquisition on July 21, 2026

Grant price $1.40 per share Recorded transaction price for the 20,000-share award

Post-transaction holdings 20,000 shares Total common shares directly owned by Flavio Mantelli after the grant

Key Terms

Grant, award, or other acquisition, COMMON STOCK

2 terms

Grant, award, or other acquisition regulatory

"transaction_code_description: Grant, award, or other acquisition"

COMMON STOCK financial

"security_title: COMMON STOCK reported as non-derivative"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did OKYO (OKYO) report for Flavio Mantelli?

OKYO Pharma reported that chief medical officer Flavio Mantelli received a grant of 20,000 shares of common stock. The transaction was recorded as a grant, award, or other acquisition on July 21, 2026, and is held as direct ownership.

How many OKYO (OKYO) shares were granted and at what price?

Flavio Mantelli was granted 20,000 shares of OKYO Pharma common stock at $1.40 per share. This value reflects the transaction price recorded for the award on July 21, 2026, under the Form 4 insider transaction report.

What is Flavio Mantelli’s ownership in OKYO (OKYO) after this grant?

Following the grant, Flavio Mantelli directly owns 20,000 shares of OKYO Pharma common stock. The Form 4 transaction report shows total shares following the transaction equal to 20,000, all classified as directly held.

What type of Form 4 transaction was filed for OKYO (OKYO)?

The transaction for OKYO Pharma was reported as a grant, award, or other acquisition of common stock. It is coded as an acquisition (Code A) of non-derivative securities rather than a market purchase or sale of existing shares.

Is the OKYO (OKYO) Form 4 transaction a derivative exercise or a stock award?

The Form 4 shows a stock award, not a derivative exercise. It involves 20,000 shares of common stock classified as a non-derivative security, with no exercise price, exercise date, or expiration date associated with options or other derivatives.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mantelli Flavio

(Last) (First) (Middle)

14-15 CONDUIT ST

(Street)

LONDON W1S 2XJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
OKYO Pharma Ltd [ OKYO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
COMMON STOCK	07/21/2026		A		20,000	A	$1.4	20,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Flavio Mantelli	07/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)